Cada año se diagnostican aproximadamente 2,5 millones de nuevos casos de cáncer de pulmón en el mundo. Las técnicas empleadas habitualmente para diagnosticar la enfermedad son invasivas y hasta pueden requerir cirugía. Unos científicos han desarroll …
In this webinar, experts from SK pharmteco’s European and North American sites share practical experience addressing these challenges across the linker-payload development lifecycle—from facility and containment strategy through process and analytical development, scale-up, cleaning, and final product release. Case-based examples will illustrate how integrated chemistry, engineering, analytical, and industrial hygiene strategies can reduce technical risk
Former ZimVie CFO Richard Heppenstall fills the vacancy created by the departure of Leo Greenstein, who is leaving Carlsmed to pursue other professional interests.
Robert Hunter will focus on UnitedHealthcare’s “modernization agenda” in the new role. It’s the latest in a slew of leadership changes at UnitedHealth as the company works to restore its image.
UnitedHealthcare names new president in latest leadership shuffle Read More »
The venture capital firm expects to launch up to eight new medtech ventures over the next five years.
Sofinnova raises 82M euros to fund medtech startups Read More »
Citing market uncertainty, the smart ring maker plans to delay a public offering that it had expected to raise up to $2.2 billion.
Newly released CMS data gives the market its first comprehensive look at how insurers are adapting to continued pressure in the privatized Medicare program. A press release stressing “stability” didn’t soften the blow.
Here’s how much insurers are cutting Medicare Advantage plans for 2027 Read More »
Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary Chugai Pharmaceutical.
Roche cuts muscle-sparing obesity drug after mid-stage disappointment Read More »
The U.S. is on the brink of a healthcare workforce crisis, according to a new report from healthcare education company Covista. But it’s not too late to try to mitigate the impact.
The results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2 study of AMT-130 underestimates disease progression.
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years Read More »
